a clinical-stage biopharmaceutical company focusing on oncology, is dedicated to revolutionizing cancer treatment through innovative approaches. Leveraging its Probody® platform technology, the company aims to transcend the limitations of current cancer therapies by pioneering a novel class of conditionally activated biologics.
The Probody® platform technology developed by CytomX is engineered to create highly potent and specific biologics activated exclusively within tumor cells, thereby minimizing the potential toxic side effects on healthy tissues.
With an extensive pipeline of candidate products in various stages of clinical development, CytomX is committed to addressing a range of solid and liquid tumor types, including lung cancer, breast cancer, pancreatic cancer, and blood cancer.
Some of CytomX’s most advanced candidate products include:
- CX-072: An antibody-drug conjugate (ADC) targeting the neurotensin receptor-1 (NTSR1) for the treatment of pancreatic cancer. CX-072 is currently undergoing phase 1/2 clinical trials.
- CX-089: An ADC targeting the somatostatin receptor 2 (SSTR2) for the treatment of pancreatic cancer, gastric cancer, and colon cancer. CX-089 is currently undergoing phase 1/2 clinical trials.
- CX-351: An ADC targeting the parathyroid hormone 1 receptor (PTH1R) for the treatment of thyroid cancer. CX-351 is currently undergoing phase 1/2 clinical trials.
CytomX stands as an innovative biopharmaceutical entity dedicated to the development of promising new cancer treatments. The Probody® platform technology holds the potential to produce highly potent and specific biologics that can significantly improve outcomes for cancer patients.